ATE530541T1 - Substituierte heteroarylpiperidinderivate als modulatoren des melanocortin-4-rezeptors - Google Patents

Substituierte heteroarylpiperidinderivate als modulatoren des melanocortin-4-rezeptors

Info

Publication number
ATE530541T1
ATE530541T1 AT08784892T AT08784892T ATE530541T1 AT E530541 T1 ATE530541 T1 AT E530541T1 AT 08784892 T AT08784892 T AT 08784892T AT 08784892 T AT08784892 T AT 08784892T AT E530541 T1 ATE530541 T1 AT E530541T1
Authority
AT
Austria
Prior art keywords
melanocortin
receptor
modulators
disorders
diseases
Prior art date
Application number
AT08784892T
Other languages
English (en)
Inventor
Holger Herzner
Michael Soeberdt
Philipp Weyermann
Sonja Nordhoff
Achim Feurer
Holger Deppe
Herve Siendt
Miroslav Terinek
Christian Rummey
Marco Henneboehle
Original Assignee
Santhera Pharmaceuticals Ch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santhera Pharmaceuticals Ch filed Critical Santhera Pharmaceuticals Ch
Application granted granted Critical
Publication of ATE530541T1 publication Critical patent/ATE530541T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
AT08784892T 2007-07-19 2008-07-18 Substituierte heteroarylpiperidinderivate als modulatoren des melanocortin-4-rezeptors ATE530541T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95067607P 2007-07-19 2007-07-19
EP07014219A EP2019100A1 (de) 2007-07-19 2007-07-19 Substituierte Heteroarylpiperidinderivate als Melanocortin-4-Rezeptormodulatoren
PCT/EP2008/005913 WO2009010299A1 (en) 2007-07-19 2008-07-18 Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators

Publications (1)

Publication Number Publication Date
ATE530541T1 true ATE530541T1 (de) 2011-11-15

Family

ID=38728783

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08784892T ATE530541T1 (de) 2007-07-19 2008-07-18 Substituierte heteroarylpiperidinderivate als modulatoren des melanocortin-4-rezeptors

Country Status (20)

Country Link
US (1) US20100249093A1 (de)
EP (2) EP2019100A1 (de)
JP (1) JP2010533666A (de)
KR (1) KR20100033541A (de)
CN (1) CN101801950A (de)
AT (1) ATE530541T1 (de)
AU (1) AU2008277916B2 (de)
BR (1) BRPI0814382A2 (de)
CA (1) CA2694480C (de)
DK (1) DK2176250T3 (de)
ES (1) ES2371626T3 (de)
HR (1) HRP20110860T1 (de)
IL (1) IL202797A0 (de)
NZ (1) NZ582153A (de)
PL (1) PL2176250T3 (de)
PT (1) PT2176250E (de)
RU (1) RU2452734C2 (de)
SI (1) SI2176250T1 (de)
WO (1) WO2009010299A1 (de)
ZA (1) ZA201000153B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010011394A (es) 2008-04-16 2010-11-12 Angus Chemical Hidrocarburos nitrados, derivados y procesos para su fabricacion.
CA2720266C (en) 2008-04-16 2016-08-23 Angus Chemical Company Process for the manufacture of nitropropanes
EP2567959B1 (de) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren
SG11201402826YA (en) 2011-12-22 2014-12-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
SI3539551T1 (sl) 2011-12-29 2022-02-28 Rhythm Pharmaceuticals, Inc. Postopek zdravljenja motenj povezanih z receptorjem melanokortin-4 v heterozigotnih nosilcih
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EA027929B1 (ru) 2012-05-25 2017-09-29 Янссен Сайенсиз Айрлэнд Юси Нуклеозиды на основе урацила и спирооксетана
US9663513B2 (en) 2012-11-20 2017-05-30 Merck Sharp & Dohme Corp. Pyrimidine PDE10 inhibitors
SG11201504554UA (en) 2012-12-21 2015-07-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
AU2016330773A1 (en) 2015-09-30 2018-04-19 Charité-Universitätsmedizin Berlin Method of treating melanocortin-4 receptor pathway-associated disorders
CA3096055A1 (en) 2018-04-06 2019-10-10 Rhythm Pharmaceuticals, Inc. Compositions for treating kidney disease
US11071730B2 (en) 2018-10-31 2021-07-27 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
EP3873903B1 (de) 2018-10-31 2024-01-24 Gilead Sciences, Inc. Substituierte 6-azabenzimidazolverbindungen als hpk1-inhibitoren
CN109879766A (zh) * 2019-03-02 2019-06-14 台州保灵药业有限公司 一种3-(nn-二甲基）氨基丁醇的合成方法
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291619B2 (en) * 2001-01-23 2007-11-06 Eli Lilly And Company Melanocortin receptor agonists
US6977264B2 (en) * 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
US20040010010A1 (en) * 2002-04-30 2004-01-15 Ebetino Frank Hallock Melanocortin receptor ligands
JP2006505531A (ja) * 2002-09-11 2006-02-16 メルク　エンド　カムパニー　インコーポレーテッド メラノコルチン−４受容体作働薬としてのピペラジン尿素誘導体
WO2005047253A1 (en) * 2003-11-12 2005-05-26 Lg Life Sciences Ltd. Melanocortin receptor agonists
US7649002B2 (en) * 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
MEP6808A (xx) * 2006-02-23 2010-02-10 Lundbeck & Co As H Priperidinoilpirodolini agonisti receptora menalokortina tipa 4
EP1842846A1 (de) * 2006-04-07 2007-10-10 Santhera Pharmaceuticals (Schweiz) AG Phenylpiperidinderivate als Melanocortin-4 Rezeptor-Modulatoren

Also Published As

Publication number Publication date
WO2009010299A8 (en) 2009-04-02
NZ582153A (en) 2011-09-30
ZA201000153B (en) 2010-09-29
ES2371626T3 (es) 2012-01-05
RU2009147775A (ru) 2011-08-27
RU2452734C2 (ru) 2012-06-10
US20100249093A1 (en) 2010-09-30
CN101801950A (zh) 2010-08-11
AU2008277916B2 (en) 2012-02-02
BRPI0814382A2 (pt) 2015-01-27
AU2008277916A1 (en) 2009-01-22
EP2176250B1 (de) 2011-10-26
EP2176250A1 (de) 2010-04-21
JP2010533666A (ja) 2010-10-28
CA2694480C (en) 2012-05-15
HRP20110860T1 (hr) 2011-12-31
EP2019100A1 (de) 2009-01-28
CA2694480A1 (en) 2009-01-22
WO2009010299A1 (en) 2009-01-22
IL202797A0 (en) 2010-06-30
SI2176250T1 (sl) 2012-01-31
DK2176250T3 (da) 2012-02-13
PT2176250E (pt) 2011-12-15
PL2176250T3 (pl) 2012-03-30
KR20100033541A (ko) 2010-03-30

Similar Documents

Publication Publication Date Title
ATE490239T1 (de) Substituierte phenylpiperidinderivate als melanocortin-4-rezeptormodulatoren
ATE530541T1 (de) Substituierte heteroarylpiperidinderivate als modulatoren des melanocortin-4-rezeptors
EA200700262A1 (ru) Арилидены для лечения заболеваний, опосредуемых эстроген-родственным рецепторам альфа
WO2004083208A8 (en) Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators
UA83917C2 (en) 3-(4-heteroarylcyclohexylamino) cyclopentanecarboxamides as modulators of chemokine receptors
JO3313B1 (ar) التراكيب والطرق لزيادة نمو العضلة
UA83311C2 (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
TW200800959A (en) Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
CL2009000374A1 (es) Compuestos derivados de piridona y piridazinona sustituidos, antagonistas de receptor mch; composicion farmaceutica; y su uso en el tratamiento de trastornos metabolicos, trastornos alimenticios, obesidad, bulimia, anorexia, diabetes, hiperlipidemia, entre otras.
HK1142775A1 (en) Therapeutic pyrazoloquinoline derivatives
IL189974A0 (en) Benzimidazole derivatives and their use for modulating the gabaa receptor complex
TW200736240A (en) Novel processes for the preparation of cyclopropyl-amide derivatives
MX2007012624A (es) Derivados de benzimidazol y su uso para la modulacion del complejo del receptor gaba-a.
DE602007012531D1 (de) Azabicycloä3.1.0ühexanderivate als modulatoren von dopamin-d3-rezeptoren
DE60313844D1 (de) Substituierte Piperidin- und Piperazin-Derivative als Melanocortin-4 Receptor Modulatoren
ATE367391T1 (de) Substituierte piperidin- und piperazin-derivate als melanocortin-4 rezeptor modulatoren
PT2016064E (pt) Métodos para a preparação de compostos contendo pirazole
WO2007098393A3 (en) Compounds and methods for treating diseases with trpv4 channel receptors
UA83142C2 (en) 3-aminocyclopentane carboxyamidine as modulators of chemokine receptors
TW200716602A (en) Novel compounds
ATE412643T1 (de) Neue 2h-chromenderivate als selektive östrogenrezeptor-modulatoren
UA84570C2 (ru) Производные циклопропила как антагонисты рецептора nk3
TW200738646A (en) Novel compounds
UA96280C2 (ru) Производные бензамидазола и их применение для модуляции рецепторного комплекса гамка
UA91998C2 (ru) Производные бензимидазола и их использование для модулирования рецепторного комплекса гамка

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2176250

Country of ref document: EP